Flash Finance

📈 Live Market Tracking

AI-Powered NSE Corporate Announcements Analysis

701
Total Announcements
335
Positive Impact
30
Negative Impact
284
Neutral
Clear
EARNINGS NEUTRAL 4/10
Vimta Labs Releases Audio Recording of Q3 FY 2025-26 Earnings Call
Vimta Labs Limited has officially released the audio recording of its Q3 FY 2025-26 earnings conference call held on January 28, 2026. This disclosure is a routine regulatory requirement under SEBI (LODR) Regulations, 2015, aimed at maintaining transparency with shareholders. The recording provides access to management's detailed commentary on the company's financial performance and strategic direction. Investors can access the full audio via the link provided on the company's official website.
Key Highlights
Audio recording of the Q3 FY 2025-26 earnings call is now available for public review. The investor call was conducted on January 28, 2026, following the quarterly results announcement. Filing is in compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements). The recording link is hosted on the company's website (vimta.com) for investor access.
💼 Action for Investors Investors should listen to the recording to understand management's perspective on growth drivers and operational challenges. This is a standard due diligence step to supplement the analysis of the reported financial numbers.
EARNINGS POSITIVE 8/10
Vimta Labs Q3 FY26 Total Income up 10.2% YoY to ₹1,005 Mn; 9M PAT Grows 16.4%
Vimta Labs reported a steady performance for Q3 FY26 with total income reaching ₹1,005 Mn, a 10.2% YoY increase. For the 9-month period (9M FY26), the company showed robust growth with revenue rising 20.7% to ₹3,043 Mn and PAT increasing 16.4% to ₹564 Mn. EBITDA margins remain healthy at 35.1% for the 9M period, supported by a strong balance sheet featuring minimal debt of ₹45.2 Mn and significant cash reserves of ₹666.6 Mn. The company continues to invest in growth, reporting a Q3 capex outflow of ₹248.3 Mn.
Key Highlights
9M FY26 Total Income grew by 20.7% YoY to ₹3,043 Mn compared to ₹2,521 Mn in 9M FY25 9M FY26 PAT increased by 16.4% YoY to ₹564 Mn with a healthy PAT margin of 18.5% EBITDA for Q3 FY26 stood at ₹344 Mn with a margin of 34.3%, despite a ₹16 Mn exceptional item for labor codes Maintains a very low Debt-to-Equity ratio of 0.01 with total debt of only ₹45.2 Mn Significant infrastructure footprint with over 600,000 sq. ft. of lab space and 1,300+ employees
💼 Action for Investors Investors should view the consistent double-digit revenue growth and strong margin profile as a sign of operational efficiency in the TIC industry. The company's extremely low leverage and high cash reserves provide a strong cushion for future expansion.
EARNINGS NEUTRAL 8/10
Vimta Labs Q3 FY26: Revenue Grows 9.7% YoY to ₹986M; PAT Steady at ₹176M
Vimta Labs reported a 9.7% YoY growth in revenue from operations for Q3 FY26, reaching ₹986.33 million. Net profit from continuing operations remained nearly flat at ₹175.86 million compared to ₹175.16 million in the previous year, largely due to a one-time exceptional charge of ₹16.16 million related to the implementation of new labour codes. For the nine-month period, the company showed stronger performance with revenue increasing 19.4% and net profit rising 16.4% YoY. The company continues to focus on its core contract research and testing services following the divestment of its diagnostics business.
Key Highlights
Revenue from operations increased to ₹986.33 million in Q3 FY26 from ₹899.23 million in Q3 FY25. Net profit for the quarter stood at ₹175.86 million, including a ₹16.16 million exceptional cost for gratuity adjustments under new labour codes. 9M FY26 total income reached ₹3,042.83 million, a significant jump from ₹2,521.41 million in the same period last year. Basic EPS for the quarter was ₹3.96, compared to ₹3.93 in the year-ago period (adjusted for the 1:1 bonus issue). The Board approved the grant of 38,269 new ESOP options to eligible employees.
💼 Action for Investors The steady revenue growth in the core testing business is positive, though margins were temporarily impacted by statutory exceptional items. Long-term investors should monitor the scalability of the National Food Testing Laboratory (PPP project) and the impact of labour code revisions on operating margins.